Abstract
In patients with chronic lymphocytic leukemia (CLL), persistence of disease after allogeneic stem cell transplantation (alloSCT) can result in poor outcomes. In an effort to improve these outcomes, patients with persistent CLL who were 90 to 100 days beyond alloSCT with no evidence of graft-versus-host-disease (GVHD) were randomized to receive lenalidomide or standard care (withdrawal of immunosuppression followed by donor lymphocyte infusion). Lenalidomide was initiated at 5 mg every other day and increased to 10 mg daily, if tolerated, in each patient. Of 38 patients enrolled, 17 (45%) met the eligibility criteria for randomization. Of these 17 patients, 8 were randomized to undergo lenalidomide therapy. Five (62%) patients had to stop taking the drug because of toxicity. The main reason for drug discontinuation was acute GVHD in 43% of patients. This incidence was 11% in the patients who were randomized to not receive lenalidomide. With a median follow-up of 2.6 years, the median survival was 3.4 years for those receiving lenalidomide. This was not reached in patients randomized to not receive lenalidomide and in patients in complete remission who were not randomized. These results suggested that treatments other than lenali...Continue Reading
References
Apr 26, 2007·British Journal of Haematology·Issa F KhouriCarlos Bueso-Ramos
Jan 25, 2008·Blood·Michael HallekUNKNOWN International Workshop on Chronic Lymphocytic Leukemia
Mar 13, 2008·Blood·Alessandra FerrajoliMichael J Keating
Jul 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lei WuJ Blake Bartlett
Sep 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mohamed L SorrorDavid G Maloney
Jul 3, 2010·Blood·Peter DregerUNKNOWN German CLL Study Group
Oct 28, 2010·Blood·Andy K HsuDavid S Ritchie
Dec 30, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christine I ChenSuzanne Trudel
Apr 2, 2011·Cancer·Issa F KhouriMarcelo Fernandez-Vina
Jun 22, 2011·Blood·Evelien KneppersMonique C Minnema
Jul 5, 2011·Blood·Xavier C BadouxAlessandra Ferrajoli
Sep 8, 2012·Leukemia·J R BrownE P Alyea
Oct 23, 2012·Experimental Hematology·Christine WolschkeNicolaus Kröger
Mar 16, 2013·Blood·Tait D ShanafeltNeil E Kay
Jun 11, 2014·Leukemia & Lymphoma·Michelle L PoonIssa F Khouri
Aug 26, 2014·Blood·Issa F KhouriAlison Gulbis
Oct 14, 2014·Bone Marrow Transplantation·J J ScarisbrickK Raj
Citations
Nov 23, 2017·Leukemia & Lymphoma·Satyen Harish GohilAmit Chunilal Nathwani
Jan 11, 2020·Hematological Oncology·Hikaru SakamotoYasushi Miyazaki
Jun 16, 2018·Bone Marrow Transplantation·Eric WongDavid Ritchie
Sep 3, 2021·Bone Marrow Transplantation·Brian PhamMehrdad Abedi